98%
921
2 minutes
20
A microfluidic hydrogel DNA microarray is developed to overcome the limitations of conventional planar microarrays such as low sensitivity, long overnight hybridization time, lack of a melting verification of proper hybrid, and complicated sample preparation process for genotyping of clinical samples. Unlike our previous prototype hydrogel array which can analyze only single-stranded DNA (ssDNA) targets, the device is the first of its type to allow direct multiplexed single nucleotide polymorphism (SNP) detection of human clinical samples comprising double-stranded DNA (dsDNA). This advance is made possible by incorporating a streptavidin (SA) hydrogel capture/purification element in a double T-junction at the start of the linear hydrogel array structure and fabricating ten different probe DNAs-entrapped hydrogels in microfluidic channels. The purified or unpurified polymerase chain reaction (PCR) products labeled with a fluorophore and a biotin are electrophoresed through the SA hydrogel for binding and purification. After electrophoretic washing, the fluorophore-labeled DNA strand is then thermally released for hybridization capture by its complementary probe gel element. We demonstrate the precise and rapid discrimination of the genotypes of five different clinical targets by melting curve analysis based on temperature-gradient electrophoresis within 3h, which is at least 3-fold decrease in incubation time compared to conventional microarrays. In addition, a 1.7 pg (0.024 femtomoles) limit of detection for clinical samples is achieved which is ~100-fold better sensitivity than planar microarrays.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bios.2015.12.068 | DOI Listing |
BMC Glob Public Health
September 2025
Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Background: Between November 2023 and March 2024, coastal Kenya experienced another wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (a total of 185 positive samples) residing in the Kilifi Health and Demographic Surveillance System (KHDSS) area (~ 900 km).
Methods: We analyzed genetic, clinical, and epidemiological data from SARS-CoV-2 positive cases across pediatric inpatient, health facility outpatient, and homestead community surveillance platforms.
Genome Biol
September 2025
Department of Clinical Pharmacy, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, 90089, USA.
Background: Recent advances in high-throughput sequencing technologies have enabled the collection and sharing of a massive amount of omics data, along with its associated metadata-descriptive information that contextualizes the data, including phenotypic traits and experimental design. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability and limit secondary analyses.
View Article and Find Full Text PDFArch Public Health
September 2025
Centre for Clinical Research, Region Värmland, Karlstad, 651 85, Sweden.
Background: Physical inactivity, impaired physical mobility and poor mental health are common in the older population and increasing as the population ages. We examined the relationships between physical activity, physical mobility, and mental health in the general population of older adults.
Methods: The study is based on 12 959 men and women aged 70 years or older answering a survey questionnaire sent to a random population sample in Mid-Sweden in 2022 (response rate 66%).
Nutr J
September 2025
Department of Life Sciences, Division of Food and Nutrition Science, Chalmers University of Technology, Gothenburg, 412 96, Sweden.
Background: Avenanthramides (AVAs) and Avenacosides (AVEs) are unique to oats (Avena Sativa) and may serve as biomarkers of oat intake. However, information regarding their validity as food intake biomarkers is missing. We aimed to investigate critical validation parameters such as half-lives, dose-response, matrix effects, relative bioavailability under single dose, and in relation to the abundance of Feacalibacterium prausnitzii, and under repeated dosing, to understand the potential applications of AVAs and AVEs as biomarkers of oat intake.
View Article and Find Full Text PDF